Loading…
Liquidia Corporation is projected to rise to $95.90 by 2027, a +23% move from its current price of $77.93. LQDA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $75.69 | $77.97 | $80.32 | +0.06% |
| Jul 14 | $74.81 | $78.02 | $81.36 | +0.11% |
| Jul 15 | $74.15 | $78.06 | $82.18 | +0.17% |
| Jul 16 | $73.60 | $78.11 | $82.89 | +0.23% |
| Jul 17 | $73.13 | $78.15 | $83.52 | +0.28% |
| Jul 18 | $72.71 | $78.19 | $84.10 | +0.34% |
| Jul 19 | $72.33 | $78.24 | $84.64 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $72.33 | $78.24 | $84.64 | +0.40% |
| Week 2 | $70.29 | $78.55 | $87.78 | +0.79% |
| Week 3 | $68.83 | $78.86 | $90.36 | +1.19% |
| Week 4 | $67.66 | $79.17 | $92.65 | +1.59% |
| Week 5 | $66.68 | $79.49 | $94.76 | +2.00% |
| Week 6 | $65.83 | $79.80 | $96.74 | +2.40% |
| Week 7 | $65.08 | $80.12 | $98.63 | +2.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Liquidia Corporation is a biopharmaceutical company that develops, manufactures, and commercializes products for rare cardiopulmonary diseases in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of PAH and PH-ILD.
In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Liquidia is trading at $76.92 per share and has a market capitalization of $6.84B, with a ranking of 1152. The current technical picture shows bullish sentiment, with RSI14 at 70, and trend indicators including SMA50 at $54.91 and SMA200 at $37.83. Near-term support sits at $55.11 and resistance is at $76.92, while the 30-day price range runs from $61.85 to $95.66.
The long-range forecast points to a rising price path with upside potential through 2050, including a 2026 average of $76.92 and a 2050 average of $982.54, with a max of $1,959.92 and a 2050 ROI of 1177.4% across years continuing bullish momentum.
A major floor 59.2% below — a decisive break under it would weaken the trend.
The nearest floor, 29.3% below — buyers have tended to step in here.
The nearest ceiling, 4.5% above — a clean break opens room to run.
A major ceiling 25.5% above — clearing it would confirm fresh momentum.
Key LQDA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LQDA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $79.86 | Sell | $79.38 | Sell |
| MA 10 | $79.06 | Sell | $78.41 | Sell |
| MA 20 | $75.75 | Buy | $75.03 | Buy |
| MA 50 | $63.08 | Buy | $65.12 | Buy |
| MA 100 | $49.66 | Buy | $55.04 | Buy |
| MA 200 | $40.50 | Buy | $44.32 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.75 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 41.71 | Neutral |
| Williams %R (14) | -47.50 | Info |
| MACD (12,26,9) | -0.45 | Sell |
| ROC (12) | 5.25 | Buy |
| Bollinger %B (20,2) | 0.63 | Neutral |
| Stochastic %K (14) | 52.50 | Neutral |
| TRIX (15) | 1.21 | Buy |
| Awesome (5,34) | 10.12 | Buy |
| Ultimate (7,14,28) | 50.43 | Neutral |
| Momentum (10) | 1.01 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 80.37 | Sell |
| ADX (14) | 39.03 | Buy |
| ATR (14) | 1.95 | Info |
The 30-day picture is bullish, with sentiment labeled BULLISH and RSI14 at 70. The 50-day simple moving average is $54.91 and the 200-day simple moving average is $37.83. Near-term support is at $55.11 and resistance at $76.92.
The 30-day price range runs from $61.85 to $95.66, indicating a potential near-term upside if price extends beyond the upper end of the range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $30.00 | $77.93 | $102.21 | 0% | Neutral | |
| $75.72 | $95.90 | $128.85 | +23% | Bullish | |
| $78.96 | $103.11 | $144.16 | +32% | Bullish | |
| $93.99 | $125.89 | $181.55 | +62% | Bullish | |
| $111.66 | $152.97 | $226.41 | +96% | Bullish | |
| $132.54 | $185.35 | $280.64 | +138% | Bullish | |
| $160.72 | $229.12 | $354.02 | +194% | Bullish | |
| $170.95 | $248.13 | $390.51 | +218% | Bullish | |
| $174.18 | $257.19 | $411.66 | +230% | Bullish | |
| $184.92 | $277.58 | $451.31 | +256% | Bullish | |
| $315.50 | $510.47 | $886.12 | +555% | Bullish | |
| $580.90 | $1,071.00 | $2,044.35 | +12.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $30.00 | $77.93 | $93.16 | +0.00% |
| August 2026 | $66.63 | $78.83 | $95.89 | +1.15% |
| September 2026 | $68.83 | $82.05 | $101.02 | +4.09% |
| October 2026 | $69.11 | $82.93 | $103.14 | +1.07% |
| November 2026 | $66.92 | $80.75 | $101.29 | -2.63% |
| December 2026 | $66.66 | $80.85 | $102.21 | +0.13% |
Click any year to see its month-by-month LQDA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect LQDA to range from $30.00 to $102.21 through 2026. The $77.93 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The LQDA price prediction for 2027 points to an average of $95.90 (low $75.72, high $128.85) — a potential gain of +23% on today's $77.93. Momentum favours further upside here.
In 2028, LQDA is projected to trade between $78.96 and $144.16, averaging $103.11 — a potential gain of +32% from today's $77.93. That is up +8% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Liquidia Corporation's 2029 outlook centres on $125.89, within a $93.99 to $181.55 range. That is up +22% on the projected 2028 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2030, LQDA could reach as high as $226.41, with a base case around $152.97 and support toward $111.66 — roughly +96% from $77.93. Buyers look set to stay in control over this stretch.
Expect LQDA to range from $132.54 to $280.64 through 2031. The $185.35 average target implies a +138% move from current prices. That is up +21% on the projected 2030 average. Momentum favours further upside here.
The LQDA price prediction for 2032 points to an average of $229.12 (low $160.72, high $354.02) — a potential gain of +194% on today's $77.93. Buyers look set to stay in control over this stretch.
In 2033, LQDA is projected to trade between $170.95 and $390.51, averaging $248.13 — a potential gain of +218% from today's $77.93. That is up +8% on the projected 2032 average. Momentum favours further upside here.
Liquidia Corporation's 2034 outlook centres on $257.19, within a $174.18 to $411.66 range. That is up +4% on the projected 2033 average. That marks a +230% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, LQDA could reach as high as $451.31, with a base case around $277.58 and support toward $184.92 — roughly +256% from $77.93. Momentum favours further upside here.
Expect LQDA to range from $315.50 to $886.12 through 2040. The $510.47 average target implies a +555% move from current prices. That is up +84% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The LQDA price prediction for 2050 points to an average of $1,071.00 (low $580.90, high $2,044.35) — a potential gain of +12.7x on today's $77.93. Momentum favours further upside here.
Investing $1,000 in LQDA today (≈ 12.832029 LQDA) could be worth
$13,743.05
+$12,743.05 (+1274%) by 2050 · US Dollar
Based on the average projected LQDA price of $1,071 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LQDAwould be worth at today's price.
$1,000 invested in LQDA on Jul 10, 2025 (≈ 70.67138 LQDA) would be worth
$5,507.42
+$4,507.42 (+450.7%) today · 5.51× · US Dollar
Based on a LQDA entry price of $14.15 vs. today's $77.93.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $78.93 | $987.33 | -1.3% |
| 1 month ago | $65.25 | $1,194.33 | +19.4% |
| 3 months ago | $38.55 | $2,021.53 | +102.2% |
| 6 months ago | $36.6 | $2,129.24 | +112.9% |
| 1 year ago | $14.15 | $5,507.42 | +450.7% |
| All time (5.0y) ago | $2.64 | $29,518.94 | +2851.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LQDA forecast.
Our base-case forecast reaches $160.00 around 2031.
Implied market cap at $160.00: $14.23B
The multi-year forecast shows bullish sentiment across most years, with projected averages increasing from 2026 through 2050. For example, 2027 average is $93.62 and 2028 average is $98.89, rising to 2030 average of $142.81 and a max of $216.83 (ROI 85.7). The outlook continues with 2040 average of $479.62 and max $864.44 (ROI 523.5), and 2050 average of $982.54 with a max of $1,959.92 (ROI 1177.4).
Max values escalate across years (e.g., 2031 max $271.45, 2032 max $358.04, 2033 max $381.12, 2034 max $393.97, 2035 max $448.19). These figures reflect an increasingly bullish trajectory but remain estimates, not guarantees, and depend on future market conditions.
Tap a question to reveal the answer.
In 2030, the forecast lists a min of $101.86, an average of $142.81, and a max of $216.83, with a projected ROI of 85.7% and a bullish sentiment.
The forecast shows bullish sentiment from 2027 onward with higher averages and ROIs (2027 avg $93.62, ROI 21.7%; 2029 avg $121.82, ROI 58.4%; 2030 avg $142.81, ROI 85.7%; 2050 avg $982.54, ROI 1177.4%). These are estimates, not guarantees.
Yes, the 2026 max is $102.98, indicating it can exceed $100 in that year; later years show higher values as well (2030 max $216.83, 2029 max $179.83).
The current price is $76.92.
The 30-day range is $61.85 to $95.66; RSI14 is 70; SMA50 is $54.91; SMA200 is $37.83; support is $55.11; resistance is $76.92; sentiment is BULLISH.
Liquidia Corporation Community Discussion
0Share your Liquidia Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.